Profound Medical becomes a publicly traded with a reverse merger, raising a $24 million private placement to back clinical testing of its prostate cancer ablation device.
Profound Medical yesterday said it's slated to hit the public markets in Canada after a reverse merger, also revealing a $24 million private placement to fuel clinical trial work.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1OMk9p6
Cap comentari:
Publica un comentari a l'entrada